Filing status
- Accounts due
- 30 September 2027
- Last accounts
- 31 December 2025
- Conf. stmt due
- 15 April 2027
- Last conf. stmt
- 1 April 2026
Dunad Therapeutics Ltd.
- Incorporated
- 2 April 2020 (6 years)
- Previously known as
- Warhead Ltd (until 14 August 2020)This list may be incomplete. See all names on Companies House
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Varun Kumar Gupta
- Accounts type
- Group
- Region
- East of England
- Address
- The Officers' MessRoyston RoadCambridgeCB22 4QH
Charges
- Total
- 2
- Outstanding
- 1
- Part satisfied
- 0
- Satisfied
- 1
Officers 5 active
Officer details are public data from the Companies House register.
Director · Appointed 14 August 2024
British
Born October 1992 (34)
Gupta, Varun Kumar, Dr
Director · Appointed 28 March 2024
Indian
Born August 1986 (40)
Corporate Secretary · Appointed 14 July 2023
Director · Appointed 21 April 2021
Dutch
Born April 1975 (51)
Director · Appointed 22 April 2020
Irish
Born July 1974 (52)
Officer history (8 former)
9 October 2026
Resigned Huang, Pearl S., Dr as Director
18 August 2026
14 August 2024
Resigned Dimitropoulos, Chris as Director
14 August 2024
31 May 2024
Resigned Gunning, Patrick Thomas, Professor as Director
28 March 2024
Appointed Gupta, Varun Kumar, Dr as Director
28 March 2024
Resigned Hodits, Regina as Director
14 July 2023
14 April 2023
12 October 2022
Appointed Gunning, Patrick Thomas, Professor as Director
12 October 2022
Resigned Kraskouskaya, Dziyana as Director
16 July 2022
Appointed Hodits, Regina as Director
16 July 2022
Appointed Dimitropoulos, Chris as Director
16 July 2022
Resigned Gunning, Patrick Thomas, Professor as Director
4 May 2022
Appointed Huang, Pearl S., Dr as Director
21 April 2021
21 April 2021
Appointed Gunning, Patrick Thomas, Professor as Director
22 April 2020
20 April 2020
Appointed Kraskouskaya, Dziyana as Director
20 April 2020
2 April 2020
Ownership 0 active
People and entities with significant control, from the Companies House PSC register
The company has declared that it has no person with significant control.
Former controllers (3)
14 August 2024
Ceased Epidarex Capital Iii UK, LP — Owns 25–50% of shares
14 August 2024
Ceased Dziyana Kraskouskaya — Holds 25–50% of voting rights (as a trust)
20 April 2020
Financials
Balance sheet as at 31 December 2025 · group accounts
- Net Assets
- (£2,248,361)
- Cash
- £287,459
- Profit
- (£11,729,168)
- Employees
- 7
- Debt Ratio
- 530%
- Current Ratio
- 1.0x
Trend
Shareholder Funds
Balance sheet detail
| 2025 | 2024 | 2023 | 2022 | 2022 | |
|---|---|---|---|---|---|
| Fixed Assets | £8,119 | £32,180 | £82,914 | £110,853 | £123,502 |
| Current Assets | £514,428 | £9,560,917 | £15,509,747 | £33,314,294 | |
| Debtors | £1,564,290 | £3,885,908 | £5,474,429 | £5,260,002 | |
| Cash | £287,459 | £7,996,627 | £11,623,839 | £25,254,899 | £28,054,292 |
| Creditors (< 1 year) | £490,170 | £902,998 | £4,341,849 | £10,443,350 | |
| Creditors (> 1 year) | £2,280,738 | ||||
| Net Current Assets | £24,258 | £8,657,919 | £22,870,944 | ||
| Net Assets | (£2,248,361) | ||||
| Shareholder Funds | (£2,248,361) | £8,690,099 | £11,250,812 | £22,320,871 | £22,994,446 |
| Turnover | £3,754,774 | £7,483,017 | |||
| Staff Costs | £1,725,043 | £2,075,425 | |||
| Operating Profit | (£1,256,051) | £420,982 | |||
| Profit Before Tax | (£1,080,445) | £451,637 | |||
| Tax | (£406,870) | (£442,511) | |||
| Profit for Period | (£11,729,168) | (£12,774,083) | (£11,488,995) | (£673,575) | £894,148 |
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 4 November 2026 | Termination of appointment of a director | |||
| 4 November 2026 | Termination of appointment of a director |
Some other companies at this address
Other companies in this industry
By trade and location
Explore the largest companies
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →